Crizotinib inhibition of ROS1-positive tumours in advanced non-small-cell lung cancer: a Canadian perspective

The ros1 kinase is an oncogenic driver in non-small-cell lung cancer (nsclc). Fusion events involving the ROS1 gene are found in 1%–2% of nsclc patients and lead to deregulation of a tyrosine kinase–mediated multi-use intracellular signalling pathway, which then promotes the growth, proliferation, a...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Curr Oncol
Autors principals: Bebb, D.G., Agulnik, J., Albadine, R., Banerji, S., Bigras, G., Butts, C., Couture, C., Cutz, J.C., Desmeules, P., Ionescu, D.N., Leighl, N.B., Melosky, B., Morzycki, W., Rashid-Kolvear, F., Lab, Clin, Sekhon, H.S., Smith, A.C., Stockley, T.L., Torlakovic, E., Xu, Z., Tsao, M.S.
Format: Artigo
Idioma:Inglês
Publicat: Multimed Inc. 2019
Matèries:
Practice Guideline
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6726257/
https://ncbi.nlm.nih.gov/pubmed/31548824
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.26.5137
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars